Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2015—Verax Biomedical has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The test is an immunoassay used on the day of transfusion at the point of care, a hospital or transfusion service, to quickly detect bacterial contamination in platelets and protect patients from receiving contaminated transfusions.
July 2015—Halozyme Therapeutics and Ventana Medical Systems announced a global agreement to collaborate on the development of a companion diagnostic assay for use with Halozyme’s investigational new drug, PEGPH20, which Ventana would ultimately commercialize.
July 2015—Seegene announced that its Allplex Gastrointestinal Full Panel Assay has received the CE-IVD mark, enabling marketing in Europe and certain other countries.
July 2015—Corgenix Medical has received U.S. FDA emergency use authorization for its ReEBOV Antigen Rapid Test. The test is to be used for the presumptive detection of Ebola Zaire virus in individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors, including geographic locations with high prevalence of Ebola infection.
July 2015—Bio SB announced a line of rabbit monoclonal antibodies, PD-L1/CD274, for immunohistochemistry with extensive protein immunogenicity analysis of targeted epitopes, high sensitivity specificity, and low background noise.
July 2015—Thermo Fisher introduced the Thermo Scientific Orbitrap Fusion Lumos Tribrid Mass Spectrometer, the newest addition to its line of Orbitrap Tribrid mass spectrometers. Designed to expand researchers’ capabilities in advanced proteomics and metabolomics applications, including targeted, data-independent acquisition and top-down analyses, the Orbitrap Fusion Lumos Tribrid has a high level of sensitivity, delivering complete protein sequence coverage and allowing scientists to perform more inclusive analyses.
July 2015—Beckman Coulter Diagnostics announced the publication of research results in Clinical Biochemistry (Storrow AB, et al. 2015;48:254–259; 260–267) that identify the precise magnitude of change in cardiac troponin required for early diagnosis of a heart attack using its Access AccuTnI+3 troponin I blood test. Beckman’s troponin-I assay has been clinically proven through a large, multicenter study and is FDA-cleared and directly aligned with the FDA’s October 2010 guidance to manufacturers of troponin tests.
July 2015—Streck’s Calibration Verification Assessment (CVA) is now assayed for the Horiba ABX Micros 60 instrument. CVA is an assayed linearity control kit used to determine the patient reportable range of three-part and five-part hematology instruments.
July 2015—MDxHealth revealed data with the aim of demonstrating the prognostic value of its ConfirmMDx for Prostate Cancer test. The data, offered in two presentations at the American Urology Association’s annual meeting in May, show the test’s ability to identify patients likely to harbor clinically significant prostate cancer from negative biopsy tissue.
July 2015—Pathology Associates Medical Laboratories has entered into a collaborative agreement with Axela to develop multiplex assays focused on immune status for vaccine preventable diseases.
